title: Total and single doses influence the effectiveness of radiotherapy in palliative treatment of plasmacytoma.
abstract: OBJECTIVE
  In a retrospective analysis of radiotherapy of plasmacytomas, the effectiveness and the prognostic factors in regard to pain reduction and recalcification were evaluated.
  
  
  METHODS
  138 patients (70 women, 68 men; 15-86 years, median 61 years) were irradiated at 272 target volumes (TVs) from January 1970 to December 2003.
  
  
  RESULTS
  In 192/225 TVs (85.3%), there was a pain reduction. The recalcification rate was 44.7% (51/114 TVs). Significant parameters for pain relief in the multivariate analysis were completeness of therapy (odds ratio [OR] 87.8; p < 0.001 vs. interruption), patients < 60 years (OR 23.0; p < 0.001 vs. >/= 70 years), and a single dose of 2 Gy (OR 11.0; p = 0.027 vs. 4-15.0 Gy). Significant parameters for recalcification in the multivariate analysis were concurrent chemotherapy (OR 12.3; p < 0.001 vs. no chemotherapy), no fractures in the TV (OR 5.9; p < 0.004 vs. fracture), and a dose of 40-< 50 Gy (OR 21.9; p = 0.035 vs. < 30 Gy) or >/= 50 Gy (OR 26.4; p = 0.033 vs. < 30 Gy)
  
  
  CONCLUSIONS
  Radiotherapy is a very effective palliative treatment. Patients with a reduced general condition, with multiple bone lesions and a poor prognosis profit from short-term schemes (e.g., 1 x 8 Gy to 10 x 3 Gy). Patients in good general condition with a life expectancy of > 1 year and an osteolysis at risk of fracture, should be treated with doses up to 40-50 Gy (20-25 x 2 Gy), in order to achieve the best possible recalcification and pain relief.
authors.affiliation: Department of Radiotherapy, University of Rostock, Rostock, Germany.
authors.forename: Thomas
authors.initials: T
authors.lastname: Stölting
authors.forename: Hellen
authors.initials: H
authors.lastname: Knauerhase
authors.forename: Gunther
authors.initials: G
authors.lastname: Klautke
authors.forename: Günther
authors.initials: G
authors.lastname: Kundt
authors.forename: Rainer
authors.initials: R
authors.lastname: Fietkau
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002114:Calcinosis / Q000473:pathology; D003131:Combined Modality Therapy; D019583:Dose Fractionation, Radiation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D015999:Multivariate Analysis; D009367:Neoplasm Staging; D010147:Pain Measurement; D010166:Palliative Care; D010954:Plasmacytoma / Q000188:drug therapy / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D011379:Prognosis; D011879:Radiotherapy Dosage; D012189:Retrospective Studies; D015996:Survival Rate; D016896:Treatment Outcome; D055815:Young Adult